Top Markets
Coin of the day
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Rang in Aktien #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Aktienkurs
$8.16
Zuletzt synchronisiert: 2025-06-26
Marktkapitalisierung
$234.57M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Regulus Therapeutics Inc. (RGLS)

Kategorie

Aktien-Split-Historie für Regulus Therapeutics Inc. (RGLS)
Die Aktie Regulus Therapeutics Inc. (Symbol: RGLS) durchlief insgesamt 2 Aktiensplits.
Der letzte Aktiensplit fand am Jun 29, 2022 statt.
Eine RGLS-Aktie, die vor dem Oct 04, 2018 gekauft wurde, entspricht heute 0.0083333333333333 RGLS-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
2022-06-29 1:10 x0.1 x0.0083333333333333
2018-10-04 1:12 x0.083333333333333 x0.083333333333333
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH